1. Dysregulation of oncogenic factors by GFI1B p32: investigation of a novel GFI1B germline mutation
- Author
-
Patrizia Noris, Marco Seri, Marie-Christine Morel-Kopp, Anna Savoia, Roberta Bottega, Caterina Marconi, Alessandro Pecci, Federica Melazzini, Tania Giangregorio, Nicole Papa, Michela Faleschini, and Valeria Bozzi
- Subjects
Hematology ,030204 cardiovascular system & hematology ,Biology ,medicine.disease_cause ,Phenotype ,03 medical and health sciences ,Exon ,0302 clinical medicine ,Germline mutation ,Chronic leukemia ,Cancer research ,medicine ,Erythropoiesis ,Carcinogenesis ,Gene ,Exome sequencing ,030215 immunology - Abstract
GFI1B is a transcription factor essential for the regulation of erythropoiesis and megakaryopoiesis, and pathogenic variants have been associated with thrombocytopenia and bleeding. Analysing thrombocytopenic families by whole exome sequencing, we identified a novel GFI1B variant (c.648+5G>A), which causes exon 9 skipping and overexpression of a shorter p32 isoform. We report the clinical data of our patients and critically review the phenotype observed in individuals with different GFI1B variants leading to the same effect on the p32 expression. Since p32 is increased in acute and chronic leukemia cells, we tested the expression level of genes playing a role in various type of cancers, including hematological tumors and found that they are significantly dysregulated, suggesting a potential role for GFI1B in carcinogenesis regulation. Increasing the detection of individuals with GFI1B variants will allow us to better characterize this rare disease and determine whether it is associated with an increased risk of developing malignancies.
- Published
- 2021